CMRX - Chimerix, Inc.

NasdaqGM - NasdaqGM Real-time price. Currency in USD
1.4500
-0.0900 (-5.84%)
At close: 04:00PM EDT
1.4400 -0.01 (-0.69%)
Pre-market: 04:04AM EDT
Stock chart is not supported by your current browser
Previous close1.5400
Open1.5700
Bid0.0000 x 2200
Ask0.0000 x 3100
Day's range1.4400 - 1.5700
52-week range1.0900 - 2.9000
Volume1,185,517
Avg. volume934,361
Market cap128.446M
Beta (5Y monthly)1.15
PE ratio (TTM)0.66
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference

    DURHAM, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Healthcare Conference on Wednesday, June 7, 2023, at 3:30 p.m. in New York City. A live audio webcast of the presentation will be available on the Investor Re

  • GlobeNewswire

    Chimerix to Participate in Cancer Moonshot Brain Cancers Forum on Glioblastoma (GBM) and Diffuse Intrinsic Pontine Glioma (DIPG) at White House

    Forum Aim is to Share Progress and Spur Actions to Advance the FieldDURHAM, N.C., May 25, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, announced that Joshua Allen, Ph.D., Chief Technology Officer of Chimerix, will participate in the Cancer Moonshot Brain Cancer Forum today at the White House in Washington, D.C. “Chimerix is deeply committed to i

  • GlobeNewswire

    Chimerix Reports First Quarter 2023 Financial Results and Provides Operational Update

    – European Union Study Authorization for Phase 3 ACTION Received, Reiterate First Efficacy Data Expected Early 2025 – – Completion of ONC206 Dose Escalation Expected by First Half 2024 – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., May 04, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the first quar

  • GlobeNewswire

    Chimerix to Report First Quarter 2023 Financial Results and Provide an Operational Update on May 4, 2023

    DURHAM, N.C., April 27, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Thursday, May 4, 2023 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2023, and to provide a business overview. To access the live conference call, please dial (646)

  • GlobeNewswire

    Chimerix Announces Presentation of Multiple Imipridone Datasets at American Association for Cancer Research Annual Meeting

    Key Presentation Highlights Ability of ONC201 to Reverse Epigenetic Signature of H3 K27M Mutation in Glioma Patients Multiple Preclinical Datasets Support Potential of Imipridone Platform DURHAM, N.C., April 18, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced a summary of presentations at the American Association for Cancer Research

  • GlobeNewswire

    Chimerix Reports Fourth Quarter and Year End 2022 Financial Results and Provides Operational Update

    - Continued Execution and Progress Towards Commercial Approval of Dordaviprone (ONC201) with Global Launch of Phase 3 ACTION Study – – Confirmed Response in Non-H3 K27M Recurrent Glioblastoma Patient During ONC206 Dose Escalation – – Strong Balance Sheet with $266 Million in Cash at Year-End and No Debt – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., March 02, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaning

  • GlobeNewswire

    Chimerix to Present at Cowen and Company 43rd Annual Health Care Conference

    DURHAM, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer, will participate in a Targeted Oncology Panel at the Cowen and Company 43rd Annual Health Care Conference on Tuesday, March 7, 2023 at 2:10 p.m. ET. An audio webcast of the panel discussion will be available on the Inve

  • GlobeNewswire

    Chimerix to Report Fourth Quarter and Year End 2022 Financial Results and Provide an Operational Update on March 2, 2023

    DURHAM, N.C., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Thursday, March 2, 2023 at 8:30 a.m. ET to report financial results for the fourth quarter and full-year ended December 31, 2022, and to provide a business overview. To access the live conference call,

  • GlobeNewswire

    Chimerix to Present at 41st Annual J.P. Morgan Healthcare Conference

    DURHAM, N.C., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer, will present a corporate presentation at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 at 12:00 p.m. PT in San Francisco, CA. An audio webcast of the presentation will be available on t

  • GlobeNewswire

    Chimerix Announces Successful Launch of ONC201 Phase 3 ACTION Study at Society for Neuro-Oncology Conference and Provides Operational Update

    – Natural Disease History study indicates median overall survival in recurrent H3 K27M-mutant diffuse glioma of 5.1 months compared to 13.7 months in the prior ONC201 Phase 2 efficacy analysis – – Two external analyses presented at SNO concluded that glioma patients who received ONC201 experienced a meaningful survival benefit – – Company to focus on Phase 3 ACTION study as potential first approval for ONC201 following interactions with U.S. Food and Drug Administration – – Following TEMBEXA tra

  • GlobeNewswire

    Chimerix Responds to Rubric Capital Management

    Highlights Confidence in Ongoing Strategy and Future Clinical Development PlansDURHAM, N.C., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, issued the following statement regarding a press release issued today by Rubric Capital Management: At Chimerix, we focus on oncology therapies most likely to have profound impact on patients and crea

  • Business Wire

    Rubric Capital Management Sends Letter to Chimerix Board of Directors

    NEW YORK, November 10, 2022--Rubric Capital Management LP ("Rubric"), an investment adviser whose managed funds and accounts collectively own approximately 8.5% of the common stock of Chimerix, Inc. ("Chimerix" or the "Company") (NASDAQ: CMRX), today sent a letter to Chimerix’s Board of Directors (the "Board").

  • GlobeNewswire

    Chimerix Reports Third Quarter 2022 Financial Results and Provides Operational Update

    – ONC201 Phase 3 ACTION Study On-Track to Open Enrollment in November – – Meeting with U.S. Food and Drug Administration (FDA) Set for Fourth Quarter – – Strong Financial Position with ~$285 Million in Cash at September 30 – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today report

  • GlobeNewswire

    Chimerix to Report Third Quarter 2022 Financial Results and Provide an Operational Update on November 3, 2022

    DURHAM, N.C., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Thursday, November 3, 2022 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2022, and to provide a business overview. To access the live conference call, please dial (6

  • GlobeNewswire

    Chimerix Announces Closing of TEMBEXA Sale to Emergent BioSolutions

    - $238 Million in Upfront Payment Received at Closing with Additional $136.5 Million in Potential Milestone Payments Plus Royalties - DURHAM, N.C., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Chimerix, Inc. (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the closing of its sale of TEMBEXA® to Emergent BioSolutions Inc. (EBS or Emergent). “The closing of our sale of TEMBEXA t

  • GlobeNewswire

    Chimerix to Present at H.C. Wainwright 24th Annual Global Investment Conference

    DURHAM, N.C., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer, will present a pre-recorded corporate presentation at the H.C. Wainwright 24th Annual Global Investment Conference made available on Monday, September 12, 2022 at 7:00 a.m. ET. An audio webcast of the presentation w

  • GlobeNewswire

    Chimerix Awarded BARDA Contract for TEMBEXA as Medical Countermeasure for Smallpox

    - Initial Procurement of 319,000 Treatment Courses for $115M with Additional Procurements at BARDA’s Discretion Over 10 Years – - Emergent BioSolutions, Inc. Payment Increases to $238M Upfront and $136.5M in Potential Milestones - DURHAM, N.C., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that is has signed a multi-ye

  • GlobeNewswire

    Chimerix Reports Second Quarter 2022 Financial Results and Provides Operational Update

    – ONC201 Phase 3 ACTION Study Planned to Initiate This Year – –~$32M in Revenue from International TEMBEXA Agreements Recently Recognized– – U.S. Anti-Trust Clearance Obtained for Sale of TEMBEXA to Emergent BioSolutions – – Conference Call at 4:30 p.m. ET Today – DURHAM, N.C., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today repor

  • GlobeNewswire

    Chimerix Appoints Christopher L. Jordan as Vice President, Regulatory Affairs

    Brings 30 Years of Experience as a Former Endocyte and Novartis Regulatory ExecutiveDURHAM, N.C., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today appointed Christopher L. Jordan as Vice President, Regulatory Affairs. “We are pleased to announce the addition of Christopher Jordan to our leadership team as VP of Regulatory Affairs.

  • GlobeNewswire

    Chimerix to Present at Wedbush PacGrow Healthcare Conference

    DURHAM, N.C., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend lives of patients facing deadly diseases, today announced that Chimerix management will participate in the Targeted Oncology panel discussion at the 2022 Wedbush PacGrow Healthcare Conference on Tuesday, August 9, 2022, at 10:20 a.m. A live audio webcast of the presentation will be available on the Investor Relations sectio

  • GlobeNewswire

    Chimerix to Report Second Quarter 2022 Financial Results and Provide an Operational Update on August 8, 2022

    DURHAM, N.C., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Monday, August 8, 2022 at 4:30 p.m. ET to report financial results for the second quarter ended June 30, 2022, and to provide a business overview. To access the live conference call, please dial (646) 307-

  • GlobeNewswire

    Chimerix Announces TEMBEXA Procurement Agreement for Approximately $25.3 Million with Public Health Agency of Canada

    DURHAM, N.C., June 24, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced Public Health Agency of Canada awarded Chimerix a contract up to $25.3 million agreement to procure TEMBEXA® (brincidofovir). Execution of this contract will be the responsibility of Chimerix, as it is expected to substantially occur prior to the close of the

  • GlobeNewswire

    Chimerix Announces $9.3 Million International TEMBEXA Procurement Agreement

    DURHAM, N.C., June 23, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced a $9.3 million agreement to procure TEMBEXA® (brincidofovir) with a third party outside of North America, with authorization from the requisite healthcare authority. Chimerix expects to promptly provide treatment courses of TEMBEXA equivalent to the total valu